Spikevax COVID-19 Vaccine Coverage Update

Published on
June 2, 2022

The Health and Human Services Commission (HHSC) updated the Medicaid and Children’s Health Insurance Program (CHIP) pharmacy benefit coverage for the Spikevax COVID-19 vaccine.

On January 31, 2022, the U.S. Food and Drug Administration (FDA) issued full approval of the Moderna COVID-19 Vaccine, now marketed as Spikevax, for individuals 18 years of age and older. Spikevax has the same formulation as the emergency use authorization (EUA) Moderna COVID-19 Vaccine and the same administration schedule. The primary series of two doses are given by a healthcare provider one month apart. The original Moderna COVID-19 vaccine is also available under the EUA. Spikevax can be used interchangeably with the EUA Moderna COVID-19 Vaccine without any safety or effectiveness concerns.

Spikevax is the brand name for the Moderna COVID-19 vaccine and has its own unique National Drug Code (NDC). Beginning June 1, 2022, Medicaid will cover the brand name Spikevax COVID-19 Vaccine NDCs in the table below for Medicaid and CHIP as a payable pharmacy benefit.

Drug name Dosage NDC
Spikevax COVID-19 Vaccine 0.5 mL 80777-0100-11
Spikevax COVID-19 Vaccine 0.5 mL 80777-0100-99